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Disintegrins and disintegrins-like proteins are able to inhibit platelet aggregation and
integrin-mediated cell adhesion. The aim of this study was to produce one disintegrin-like
cloned from Bothrops leucurus venom gland and to characterize it regarding biological
activity. The recombinant protein was puriﬁed by one step procedure involving anion-
exchange chromatography (DEAE-cellulose) and presented a molecular mass of
10.4 kDa. The puriﬁed protein was able to inhibit platelet aggregation induced by collagen
(IC50 ¼ 0.65 mM) and to inhibit growth of Ehrlich tumor implanted in mice by more than
50% after 7 days administration of 10 mg/day. No effects were observed upon adenosine 50-
diphosphate (ADP)-and arachidonic acid (AA)-induced platelet aggregation. The
recombinant protein was recognized by an antibody speciﬁc for jararhagin one metal-
loproteinase isolated from Bothrops jararaca venom, and therefore it was named leucur-
ogin. Anti-angiogenesis effect of leucurogin was evaluated by the sponge implant model.
After 7 days administration leucurogin inhibited, in a dose dependent way, the vascular-
ization process in the sponge. Leucurogin represents a new biotechnological tool to
understand biological processes where disintegrins-like are involved and may help to
characterize integrins that can be involved in development and progression of malignant
cells.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Bothrops snake venoms are a complex mixture of bio-
logical active peptides and proteins (Kini and Evans, 1990;
Rosing and Tans, 1992), which can cause local and
systemic lesions including pain, edema, hemorrhage, tissuee Minas Gerais, Av
Minas Gerais, Brazil.
).
. All rights reserved.necrosis, and blood coagulation disorders (Barraviera,
1994; Fonseca, 2001; Melo et al., 2005; Markland, 1998).
Snake venom metalloproteinases (SVMPs) are members of
the super family of zinc-dependent proteinases (Jia and
Pérez, 2010; Oliveira et al., 2010; Markland, 1998) and are
associated with hemorrhagic and ﬁbrinolytic activities of
the venoms (Lou et al., 2005). Based on their cDNA and
structural domains SVMPs are classiﬁed into four major
groups: PI to PIV Bjarnason and Fox (2004). Members of
class PI (20–30 kDa) contain only the zinc-dependent
proteolytic domain. Class PII members (30–50 kDa)
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disintegrin domain presents RGD (Arg-Gly-Asp) or KGD
(Lys-Gly-Asp) sequences characteristic of disintegrins,
responsible for bindingwith integrins. Free disintegrins can
be found in the snake venom as 5–10 kDa hydrolysis
products of class PII members. Class PIII members (50–
65 kDa) are comprised of three domains, the proteolytic,
the disintegrin-like and the cysteine rich domains. In
contrast to PII disintegrins, free disintegrin-like domains
are not found in the snake venom. Instead, hydrolysis of
class PIII members leads to the production of fragments
containing both the disintegrin-like and the cysteine rich
(dis-cys) domains (Selistre de Araujo et al., 2005; Cidade
et al., 2006). These dis-cys proteins are larger than RGD
disintegrins presenting molecular mass in the range of 27–
30 kDa. In addition, the disintegrin-like domains present
XECD (X-Asn-Cys-Asp) motif instead of RGD/KGD tripep-
tide characteristic of disintegrins. Class PIV members
(95 kDa) have, in addition to the class PIII domains, a leci-
thin domain.
The participation of integrins in inﬂammatory process,
vascular diseases and cancer is well known. Therefore the
characterization of integrins antagonists is an interesting
subject of study and disintegrins appears as putative
candidates to be used as effective tools for cancer therapy.
On the other hand, the biological activity of the conjugate
dis-cys is not yet clear. Alternagin C, a 29 kDa dis-cys from
Bothrops alternatus is able to promote adhesion, migration
and endothelial cell proliferation after binding to a2ß1
integrin (Selistre de Araujo et al., 2005). The a2ß1 integrin is
a major collagen receptor that plays an essential role in the
adhesion of normal and tumor cells to the extracellular
matrix (Selistre de Araujo et al., 2005). Jararhagin, the most
well characterized class PIII metalloproteinase isolated
from Bothrops jararaca was described to inhibit, in vitro,
platelet aggregation induced by type I collagen-a2ß1
integrin interaction (Moura da Silva et al., 2001; Zigrino
et al., 2002). Tanjoni et al. (2010) showed that a2ß1 integ-
rin may interact with two different sites in the jararhagin,
the ECD-motif located at the disintegrin-like domain and
with another motif located at the cysteine rich domain. The
aim of this study was to produce, using Pichia pastoris
expression system, the disintegrin-like domain from
Bothrops leucurus SVMP and to determine the activity of
this recombinant protein upon platelet aggregation and
tumor growth. The recombinant protein, named leucur-
ogin, presents 10.4 kDa and is produced in very high
amounts in our yeast system. Our results show that leu-
curogin is able to inhibit platelet aggregation induced by
collagen and Ehrlich tumor growth. In a sponge implant
model leucurogin showed to be able to potently inhibit
vascularization process.
2. Materials and methods
2.1. Chemical products
DEAE-cellulose was a product from Pharmacia (Uppsala,
Sweden). The hollow-ﬁber systemwas from GE Healthcare
(Uppsala, Sweden). Collagen and ADP were from Helena
Laboratories (Beautmont, TX, USA).2.2. Venom gland and antibody
One gland from an adult B. leucurus was collected and
stored at 80 C until use. Polyclonal anti-jararhagin anti-
serumwas kindly supplied by Dr. Ana Moura from Instituto
Butantan, Sao Paulo, Brazil and was produced as described
by Harrison et al. (2000).
2.3. Animals
Swiss male mice, 25–30 g body weight were used for
biological assay. The experiments reported here were per-
formed according to the guidelines established by the
Brazilian College for Animal Experimentation (COBEA) and
by local animal Ethics Committee.
2.4. Cloning of disintegrin cDNA
Total RNA was extracted from venom gland using Trizol
(Promega, Madison, WI, USA). Primer sequences, estab-
lished considering the disintegrin domain of jararhagin
(Paine et al., 1992), contained Xho I restriction site in the
KEX2 cleavage site for the sense (CTCGAGAAAAGA-
GAGGTGGGAGAATGTGAC) and Xba I restriction site
followed by stop codon for anti-sense (AGATCTCTAC-
TTATGGAAGACATCTGC). The RT-PCR product was cloned
into pGEM-T easy vector (Promega, Madison, WI, USA) and
after sequencing it was subcloned into pPIC9 vector (Invi-
trogen, Carlsbad, California, USA). The sequencing of cDNA
was carried out by the BigDye Terminator Ready Reaction
Mix kit from Applied Biosystems and resolved in a 3130XL
sequencer (Foster, CA, USA). The pPIC9 containing the dis-
integrin sequence was linearized using Bgl II, the fragment
containing the disintegrin segment was puriﬁed and used
to transform the MDS 1168 P. pastoris strain (Invitrogen,
Carlsbad, CA, USA) by electroporation (1500 V, 25 mF, 400U).
Positive clones were identiﬁed by replica-plating of colo-
nies on methanol containing plates.
2.5. Expression and puriﬁcation
For protein expression the procedure was as previously
described by Santos et al. (2010). Positive clones were
plated on solid yeast extract peptone dextrose (YPD)
medium and incubated for 48 h at 30 C. The cells were
inoculated into 25 mL of buffered minimal glycerol (BMGY)
medium, pH 6. At DO600 between 2 and 6, the cell
suspension was centrifuged and the pellet resuspended
into 100mL of bufferedminimal methanol (BMM)medium.
The protein expression was induced by addition of meth-
anol to a ﬁnal concentration of 0.5% in the medium.
Samples from the medium were collected at time zero and
after each 24 h intervals until 72 h. The expressed protein
was puriﬁed from the fermentation medium by tangential
ﬁltration in a hollow-ﬁber system using a 5 kDa cutoff
membrane. The concentrated protein from the tangential
ﬁltration was dialyzed against 20 mM Tris–HCl buffer pH
8.4 and loaded in a DEAE-cellulose (2 3 cm) column on an
FPLC system (Pharmacia, Uppsala, Sweden). The column
was equilibrated and elutedwith 20mMTris–HCl buffer pH
8.4 at a ﬂow rate of 1 mL/min. Adsorbed proteins were
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500 and 1000 mM) in the 20 mM Tris–HCl buffer pH 8.4.
Protein concentrationwas estimated using the Proteoquant
reagent (Proteobras, SP, Brazil) as described by Bradford
(1976) and the bicinchoninic acid method (Smith, 1985).
2.6. Western-blotting
Western blot was performed with denatured protein
separated in a 12% sodium dodecylsulphate-polyac-
rylamide gel electrophoresis (SDS-PAGE). Proteins were
transferred to a polyvinylidene ﬂuoride membrane (PVDF;
Bioagency, Hamburg, Germany). Blots were blocked at
room temperature with 2.5% non-fat dry milk in phosphate
buffered saline (PBS) plus 0.1% Tween 20 (PBS-T) before
incubation with rabbit anti-jararhagin antiserum (diluted
1:2000). The immunecomplexes were detected by chemi-
luminescent reaction (ECLþ kit, Amersham GE Healthcare,
Uppsala, Sweden).
2.7. Platelet aggregation
Te recombinant protein was tested for the effect upon
platelet aggregation using fresh human platelet rich plasma
(PRP) as described by Higuchi et al. (2007). A PACKS-4
platelet aggregation chromogenic kinetic system (Helena
Laboratories, Beautmont, TX, USA) was used to platelet
aggregation monitoring. Inhibition of adenosine 50-
diphosphate (ADP)-, arachidonic acid (AA)-, and collagen-
induced platelet aggregation was conducted at 37 C by
adding the recombinant protein (0.5–3 mM ﬁnal concen-
tration) 3 min before the addition of the agonist (ﬁnal
concentrations: ADP, 10 mM; AA, 30 mg/mL and collagen,
5 mg/mL).
2.8. Ehrlich tumor
Ten days after intraperitoneal inoculation of cells in
mice, the ascitic tumor was removed and the cells sepa-
rated by centrifugation at 3000g for 3 min. After washing
the cells with saline, the cellular viability was determined
using Trypan blue. Samples presenting cellular viability
lower than 90% were discarded. Viable cells (2.5  106)
were inoculated subcutaneously in mice and in the eighth
day after inoculation the treatment was initiated and lasted
seven days with daily subcutaneous injections (Higuchi
et al., 2007). Groups of 20 mice were treated with three
different doses of puriﬁed recombinant protein (5, 10 or
20 mg per animal per day) or 20 mg of protein from
fermentation medium without methanol induction.
Samples were administered subcutaneously until the 7th
day (7 doses) and at the 8th day the animals were sacriﬁced
and the tumor removed and weighed. Animals from the
control group received injections of 100 mL 0.9% saline.
2.9. Angiogenesis in sponge disc implant
Angiogenesis was determined indirectly by the sponge
implant model in mice (Santos et al., 2010). Polyurethane
sponge discs (Vitafoam Ltd., London, UK), 8 mm diameter
and 5 mm thick were used as the matrix for ﬁbrovasculartissue growth. The sponge discs were sterilized overnight
in 70% ethanol and by boiling in distilled water for 15 min
before the implantation. The animals were anesthetized by
intraperitoneal injection of 2.5% tribromoethanol (Sigma
Chemical Co., St Louis, MO, USA) 1 mL/100 g body weight.
The sponge discs were aseptically implanted into a subcu-
taneous pouch. The animals with implant had been
randomly divided into two groups (n ¼ 10 each group).
Treatment initiated 24 h after the implantation with
subcutaneous daily injections of puriﬁed recombinant
protein (10, 25 or 50 mg per animal per day). The control
group received daily injections of 100 mL 0.9% saline. In the
eleventh day after the beginning of treatment (ten doses),
the implanted bearing mice were anesthetized by intra-
peritoneal injection of tribromoethanol and killed by
cervical dislocation. The sponge was removed, dissected
free from adherent tissue, weighed and homogenized for
hemoglobin quantitation.
2.10. Hemoglobin measurement
Hemoglobinwas quantiﬁed by a colorimetric method as
described by Santos et al. (2010). Hundredmilligrams of the
sponge implant were excised carefully. Each piece was
homogenized in 2.0 mL Drabkin reagent (Labtest, São
Paulo, Brazil) and centrifuged at 10000g for 15 min. The
supernatants were ﬁltered through a 0.22 mm ﬁlter (Milli-
pore, Bedfor, MA) and the hemoglobin in the samples was
determined spectrophotometrically at 540 nm. The amount
of hemoglobin was calculated from a known amount used
as standard assayed in parallel. The results were expressed
as mg Hb mg1 of wet tissue.
2.11. Statistical analysis
A two-tailed, unpaired Student’s t test was done to
determine statistical signiﬁcance by the probability of
difference between the means. p < 0.05 was considered
statistically signiﬁcant. Values are expressed as mean  SE.
3. Results
3.1. Cloning of the disintegrin-like
The sequence of the disintegrin-like cDNApresented 279
bp long with the deduced sequence containing 93 amino
acids (Fig. 1). The putative primary structure includes 15
cysteine residues and the ECD-motif, the molecular mass
was estimated as 10.4 kDa and the isoelectric point 4.1. The
protein is 98% homologous to the disintegrin-like segment
of jararhagin and 66% homologous to the disintegrin-like
segment of leucurolysin-B (leuc-B, Sanchez et al., 2007),
an SVMP present in the B. leucurus venom (Fig. 2) and
therefore was named leucurogin.
3.2. Expression and puriﬁcation of leucurogin
Leucurogin was successfully expressed by P. pastoris.
Salts were removed and the protein concentrated using the
hollow-ﬁber system. The protein was puriﬁed by one
chromatography step process involving ion exchange on
Fig. 1. Leucurogin and the domains of SVMP-III family proteins. These
domains include a signal sequence (p), a pro-domain (pro), the metal-
loproteinase domain (MP), a disintegrin domain (dis), a spacer (s) and the
cysteine rich domain (cys).
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buffer containing 200 mM NaCl (Fig. 3A). Fractions con-
taining puriﬁed leucurogin were pooled (showed by hori-
zontal line) and loaded on SDS-PAGE. As shown in the
Fig. 3B the puriﬁed protein presented one band of
approximately 10.4 kDa.
3.3. Western blotting
Leucurogin presented 98% homology with jararhagin’s
disintegrin-like domain. Therefore, we utilized an anti-
jararhagin antibody for the characterization of its immu-
nological properties. Leucurogin was recognized by
anti-jararhagin antibody (Fig. 4B). As can be seen in Fig. 4A,
a second band corresponding to molecular mass of 27 kDa,
present in a partially puriﬁed fraction of the venom,
probably the dis-cys product of hydrolysis of some SVMP
from B. leucurus venom and a third band from the crudeFig. 2. Amino acid alignment. Sequences of leucurogin (leuc), jararhagin (jar, Pai
disintegrin sequences (bold). Amino acids not homologous with jararhagin are undvenom (V), corresponding to molecular mass around
60 kDa, probably one native metalloproteinase, were also
recognized by that antiserum. Crude venom and P2 are
fractions from a puriﬁcation process described by Sanchez
et al. (2007).
3.4. Platelet aggregation
Leucurogin showed to be able to inhibit collagen-
induced platelet aggregation but not the one induced by
ADP (Fig. 5) or AA. At 0.65 mM leucurogin inhibited 50% of
platelet aggregation. At 1.3 mM leucurogin was able to
inhibit 100% of platelet aggregation induced by collagen.
3.5. Ehrlich tumor
Tumor mass was evaluated on the 8th day after the
beginning of treatment. Leucurogin administration inhibi-
ted 30% the tumor growth even at the lower dose of 5 mg/
day (0.48 nmol/day) when compared to the control (saline)
or with the injection of protein (20 mg/day) from the non-
induced fermentation medium (Fig. 6A). Administration
of 0.96 nmol (10 mg/day–300 mg/kg/day) of the puriﬁed
leucurogin signiﬁcantly inhibited the growth of experi-
mental Ehrlich tumor bymore than 50% as compared to the
saline (Fig. 6B). The tumor mass from animals treated with
10 mg/day leucurogin was 0.23  0.06 g, and the mass from
the group treated with 0.9% saline was 0.49  0.09 g.
3.6. Angiogenesis in sponge disc implant
Angiogenesis was evaluated at day 11 after the begin-
ning of treatment. Neovascularization was also measuredne et al., 1992), and leucurolysin-B (leuc-B, Sanchez et al., 2007) showing
erlined.
Fig. 3. Leucurogin puriﬁcation. A, Proﬁle obtained in DEAE-cellulose (2  3 cm). Fractions of 2 mL were collected. The horizontal bar refers to the active pooled
fractions. B, Polyacrylamide gel electrophoresis (12%) under reducing conditions of leucurogin (Leuc) eluted from ionic exchange (200 mM) chromatography. The
gel was silver stained. The arrow indicates the leucurogin band. M, molecular mass marker (Bench marker ladder, Invitrogen). OD ¼ optical density.
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sponge. There was a signiﬁcant decrease (w82%) in the
hemoglobin levels in the sponge of animals treated with
10 mg/day of leucurogin and at 50 mg/day the decreasing
was around 100% (Fig. 7).
4. Discussion
Bothrops snake venoms are rich sources of metal-
loproteinases, enzymes involved in the hemorrhagic
process caused by the venom Bjarnason and Fox (2004).
These proteinases, by autolysis, may generate someFig. 4. Western-blot analysis. Samples were electrophoresed in 12% poly-
acrylamide gels and electroblotted to PVDF membranes. A polyclonal anti-
body anti-jararhagin was used for detection. This gel is representative of 3
experiments with similar results. A) V, crude venom containing native
metalloproteinases of B. leucurus, P2 - fraction from B. leucurus venom
(Sanchez et al., 2007), M - molecular mass marker (Bench marker ladder,
Invitrogen) and B) leucurogin (L) 2, 5, 10 or 20 mg.bioactive fragments known as disintegrins or the conjugate
dis-cys depending of the snake species (Takeda et al.,
2006). A growing body of evidences showing the ability
of disintegrins to inhibit platelet aggregation and its effects
involving the largely distributed membrane receptors
integrins has been accumulated in the literature. It was
observed in our lab that one proteinic fraction, partially
puriﬁed from B. leucurus venom, is able to inhibit tumor
growth implanted in mice. This fraction, presenting
a 27 kDa protein is able to inhibit Ehrlich tumor growth by
60%when subcutaneously injected in themice at 300 mg/kg
body weight/day during 9 days (unpublished data). We
believed that the effect upon tumor growth was due to the
27 kDa protein, probably one dis-cys conjugate. As the
biological effects of dis-cys conjugate are not well deﬁned,
if attributed to the disintegrin-like or to the cysteine rich
domain, we decided, for a better biological characteriza-
tion, to produce the recombinant disintegrin-like segment.
Recombinant DNA techniques gives us the possibility to
obtain, in large amounts, proteins not found in nature in
a free form, allowing the study of their putative biological
properties, therefore providing pivotal tools to understand
different biological processes.
Recent studies have examined the participation of
integrin–disintegrin interaction in physiological and path-
ophysiological processes (Takeda et al., 2006; Kamiguti
et al., 1998; Clemetson, 1998). Due to their ability to
inhibit adhesion, disintegrins may represent potential tools
for cancer therapy since adhesion is an important step for
angiogenesis development. Jararhagin C, a 30 kDa dis-cys
hydrolysis product of jararhagin (Moura da Silva et al.,
1999; Usami et al., 1994) and halydin, the ﬁrstly described
recombinant disintegrin-like (You et al., 2003), are potent
inhibitors of platelet aggregation. Leucurogin, the ECD
recombinant disintegrin-like described in this study
showed to be active against tumor growth. Leucurogin is
66% homologous to the disintegrin-like segment of
leucurolysin-B, one SVMP class III isolated from B. leucurus
venom (Sanchez et al., 2007). This result shows that the
Fig. 5. Effect of leucurogin on platelet aggregation. Platelets-rich plasma
were pre-incubated at 37 C for 2 min without (A) and in the presence of
leucurogin at concentrations 0.65 mM (-) and 1.3 mM (:) before the
addition of 5 mg/mL collagen. (x) control, without collagen as an agonist of
the process. The experiments were repeated at least three times.
Fig. 7. Angiogenesis level in implanted sponge evaluated in the 11th day
after beginning of treatment with saline (S) or with 10, 25 or 50 mg of leu-
curogin/animal/day). A) hemoglobin levels determined colorimetrically and
expressed as microgram per milligram of wet weight of sponge. B) Illus-
trations of sponges after treatment. Results represent the mean  SEM of ten
animals for each group. *p < 0.05 when compared to control (S).
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contains more than one type of dis-cys conjugate.
Leucurogin used in the biological assays in this study
was puriﬁed by a very simple procedure involving one
chromatographic step after clariﬁcation in a hollow-ﬁber
system. As observed for most recombinant proteins, leu-
curogin has a strong tendency to aggregate in low ionic
strength (data not shown). Puriﬁed leucurogin was ﬁrstly
assayed for inhibition of platelet aggregation and the
results showed that the recombinant protein is as active asFig. 6. Effect of leucurogin upon tumor growth. A) Tumor mass in male
Swiss mice inoculated with Ehrlich tumor. Animals were divided in groups
and treated with disintegrin with daily injections of 5, 10 or 20 mg/day for
seven days. In the animals from control group it was injected 100 mL of saline
(S). For fermentation control it was used a sample of fermentation medium
without disintegrin (C) in a dose of 20 mg protein/day. *p < 0.05 vs S.
**p < 0.01 vs saline. B) Illustrations of tumors: animals treated with saline
(S) or with 20 mg per day of leucurogin (Leuc).the other natural disintegrins or dis-cys conjugates like that
from B. jararaca (Usami et al., 1994) and Bothrops atrox (Jia
et al., 1997). At micromolar levels leucurogin is able to
inhibit 100% of platelet aggregation induced by collagen. No
effects were observed upon platelet aggregation induced
by ADP or AA. The capacity of leucurogin to inhibit the
growth of Ehrlich tumor implanted in mice was also similar
to that observed for the 27 kDa protein partially puriﬁed
from B. leucurus snake venom. By the vascularization levels
of a sponge subcutaneously implanted in mice we can
conclude that at least partially the effect of leucurogin upon
the tumor growth may be due to a potent inhibition of
angiogenesis process. Previous studies have shown that
hemoglobin detection correlated well with other methods
for the detection and quantiﬁcation of angiogenesis in
tissues (Hu et al., 1995).
In conclusion, this work describes, for the ﬁrst time, the
production of one recombinant disintegrin-like cloned
from B. leucurus and shows that this disintegrin, indepen-
dently of the cysteine rich domain, is able, probably
through interaction with integrins a1b1 or a2b1, to inhibit
effects elicited by type I collagen like platelet aggregation
and tumor growth. Leucurogin represents a new tool to
understand the biological process where disintegrins-like
are involved and may help to characterize integrins that
can be involved in development and progression of
malignant cells.
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